Interleukin-1 beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

---

Atıf İçin Kopyala

Gül A., Tugal-Tutkun I., Dınarello C. A., Reznıkov L., Esen B. A., Mırza A., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.71, ss.563-566, 2012 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 71
• Basım Tarihi: 2012
• Doi Numarası: 10.1136/annrheumdis-2011-155143
• Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.563-566
• İstanbul Üniversitesi Adresli: Evet

Özet

Objective Uveitis and retinal vasculitis are sight-threatening manifestations of Behcet's disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recombinant humanised anti-interleukin 1 beta antibody, in Behcet's disease patients with uveitis.